Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity.
about
Towards Clinical Application of Neurotrophic Factors to the Auditory Nerve; Assessment of Safety and Efficacy by a Systematic Review of Neurotrophic Treatments in Humans.Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevitySystemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's diseaseDrug delivery systems, CNS protection, and the blood brain barrierActivation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood-brain barrier using focused ultrasound and microbubbles.Multiphoton microscopy guides neurotrophin modification with poly(ethylene glycol) to enhance interstitial diffusion.Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.PEGylation of interleukin-10 for the mitigation of enhanced pain states.The behavioral and biochemical effects of BDNF containing polymers implanted in the hippocampus of rats.Prodrug based optimal drug delivery via membrane transporter/receptor.Combination of therapeutic hypothermia and other neuroprotective strategies after an ischemic cerebral insultRecent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future.Alzheimer's disease drug development and the problem of the blood-brain barrier.PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution.From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF)Neurotrophin strategies for neuroprotection: are they sufficient?Growth factor conjugation: strategies and applications.Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.Brain-Derived Neurotrophic Factor Loaded PS80 PBCA Nanocarrier for In Vitro Neural Differentiation of Mouse Induced Pluripotent Stem Cells.Estrogen receptor β deficiency impairs BDNF-5-HT2A signaling in the hippocampus of female brain: A possible mechanism for menopausal depression.Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses.The role of neurotrophic factors conjugated to iron oxide nanoparticles in peripheral nerve regeneration: in vitro studies.Delivery of brain-derived neurotrophic factor via nose-to-brain pathway.Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury.Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.Neurotrophic growth factor responses to lower body resistance training in older adults.Brain-derived neurotrophic factor secreted by the cerebral endothelium: A new actor of brain function?Encapsulation and Delivery of Neutrophic Proteins and Hydrophobic Agents Using PMOXA-PDMS-PMOXA Triblock Polymersomes
P2860
Q28067169-47942199-3B51-4AAC-9F71-E4C3989E6594Q28344427-394ABF16-66B5-41E0-BC40-59CA9C19B056Q28488296-84F5242C-0FF0-4AFE-A458-BA0026CA4ADBQ30432845-0C819B00-6DEB-4A4D-8FE2-11E7DD11514EQ30443197-553AA409-558B-4CDD-B776-90B237521A10Q33204009-CB625ED5-D3A2-4FA0-B631-7D4B5FF90ED2Q33336647-AB747C6D-7B3C-4D13-899B-E64819057D64Q33505369-40460E64-0C9F-4D37-B831-D8B9638ECB71Q33712487-136B7DE1-2AF0-4B5A-8B8A-1517865A7859Q34452034-43707B24-CE69-4541-876D-AA6771110046Q34567563-EA906BE1-8674-467D-B1A3-27F30514A487Q35040802-AD702D96-4E17-4EAA-BDD6-574286DE9F26Q37374635-CAF95A5F-DC6E-40E8-A42A-901C5B4E80DDQ37708777-355703EA-655A-4C58-A6B8-240C25C6CDF2Q38168376-98FD997B-E9C1-4973-A548-FB227F20ADCDQ38194485-5649A4BE-3844-4659-8702-1197BE302087Q38204731-4959D2A3-8458-450E-810D-438A894F1DC4Q38587566-4E524074-CD16-43EE-BCF2-8742287E9967Q38710968-19534B2D-E830-4E90-A91B-F281B6518611Q38763596-3A5D3554-07CC-400C-832F-EFDCB28A41DAQ41973261-31418B44-DBEB-43E4-BD05-4F0188088EA7Q42181057-A0460400-FE36-47B3-8F76-A6FC2EA656C4Q42380871-78E0089E-F0FA-45E3-BC4A-919FF786438BQ47422073-DE7AC10D-A4AE-4AFC-8891-85AA1A65C26DQ47606935-2AE6EE12-A707-4611-8923-AD7CB0B4CCCBQ48899583-ADD733AD-A3DD-4575-A290-128FFB9C5349Q52647021-EFBE0E05-8DA0-4EBA-AE71-6B9F2593C9A1Q58580983-9B545CE6-8629-4CDC-9A77-942EB96B660A
P2860
Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Carboxyl-directed pegylation o ...... mal loss of biologic activity.
@en
Carboxyl-directed pegylation o ...... mal loss of biologic activity.
@nl
type
label
Carboxyl-directed pegylation o ...... mal loss of biologic activity.
@en
Carboxyl-directed pegylation o ...... mal loss of biologic activity.
@nl
prefLabel
Carboxyl-directed pegylation o ...... mal loss of biologic activity.
@en
Carboxyl-directed pegylation o ...... mal loss of biologic activity.
@nl
P356
P1476
Carboxyl-directed pegylation o ...... mal loss of biologic activity.
@en
P2093
P304
P356
10.1023/A:1012117815460
P577
1997-08-01T00:00:00Z